- CH₣232.94bn
- CH₣265.12bn
- $56.33bn
Brief: Novartis - Data Shows 58% Lower Risk Of Psa Progression With Pluvicto In Prostate Cancer
Health Rounds: Common ADHD medicines help treat cancer-related fatigue
Brief: Novartis AG - Denton Site Expected To Be Operational In 2028 And Create New Us Jobs
Bayer's experimental blood thinner cuts risk and severity of repeat strokes (updated)
Novartis to cut 220 jobs as it closes German site (updated)
Novartis to cut 220 jobs as it closes German site
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Swiss stocks - Factors to watch on May 4
Brief: Novartis Receives Health Canada Approval For Fabhalta Oral Treatment For Adults With C3G
Judge at drug industry's urging blocks North Dakota discounted medications law
Judge at drug industry's urging blocks North Dakota discounted medications law
UCB falls on Novartis' results read-across
Live Markets: SOX puppets
Live Markets: An uneasy lull
Brief: Novartis CFO Says Companies That Signed US Deals Will Have To Be Very Cautious Around Pricing Of Drug Launches In MFN Countries
Novartis falls premarket after weaker Q1 results
Live Markets: Europe before the bell: No war, no peace
Brief: Novartis CEO Says 'Very Constructive' Engagement With Swiss Government Being Had On Finding Solution Around US MFN Policy